| scholarly article | Q13442814 |
| P50 | author | Andy C Rawstron | Q38544276 |
| Maryalice Stetler-Stevenson | Q90926259 | ||
| P2093 | author name string | Bruno Paiva | |
| P2860 | cites work | Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma | Q33621587 |
| International uniform response criteria for multiple myeloma. | Q34549410 | ||
| Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. | Q35134983 | ||
| Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction | Q35222117 | ||
| Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma | Q35848236 | ||
| Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system | Q35849614 | ||
| High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. | Q36683750 | ||
| Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation | Q36969778 | ||
| Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders | Q37082345 | ||
| Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. | Q37087424 | ||
| How should we treat newly diagnosed multiple myeloma patients? | Q38169677 | ||
| Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study | Q43821016 | ||
| Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation | Q44182912 | ||
| Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. | Q44267559 | ||
| Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. | Q45785426 | ||
| Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. | Q46027082 | ||
| Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma | Q46304736 | ||
| A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control | Q46440869 | ||
| Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. | Q47996009 | ||
| Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma. | Q54300494 | ||
| High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. | Q54309630 | ||
| Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium | Q56461029 | ||
| Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance | Q58050864 | ||
| Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile | Q60203403 | ||
| Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients | Q60203477 | ||
| High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma | Q60203492 | ||
| Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials | Q60203544 | ||
| Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma | Q60203595 | ||
| The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients | Q60203704 | ||
| Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. | Q64942570 | ||
| Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma | Q83608464 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 21-25 | |
| P577 | publication date | 2015-07-22 | |
| P1433 | published in | Cytometry Part B: Clinical Cytometry | Q15764840 |
| P1476 | title | Assessment of minimal residual disease in myeloma and the need for a consensus approach | |
| P478 | volume | 90 |
| Q49641900 | Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry |
| Q38881884 | Diagnosis of chronic lymphoproliferative disorders by flow cytometry using four-color combinations for immunophenotyping: A proposal of the Brazilian Group of Flow Cytometry (GBCFLUX). |
| Q47438586 | Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. |
| Q36705534 | Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study |
| Q92903027 | Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy |
| Q38832525 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma |
| Q40968571 | Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease |
| Q88592246 | Issue Highlights-May 2018 (94B3) |
| Q38852886 | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. |
| Q89776894 | MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods |
| Q92198990 | Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease |
| Q93088915 | Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives |
| Q50092746 | Minimal residual disease analysis in myeloma - when, why and where. |
| Q90080683 | Monitoring minimal residual disease in the bone marrow using next generation sequencing |
| Q46809405 | Myeloma minimal residual disease testing in the United States: Evidence of improved standardization |
| Q42050819 | Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. |
| Q89047536 | Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma |
| Q91622598 | Should we be routinely testing for circulating clonal plasma cells in patients with multiple myeloma? |
| Q64098104 | Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma |
| Q50197867 | Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms |
| Q38681814 | Utilizing next-generation sequencing in the management of multiple myeloma. |
| Q96340770 | Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma |
Search more.